Search results for "amyloid precursor protein"

showing 10 items of 134 documents

SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer’s disease

2014

Abstract We present the design, synthesis and biological evaluation of compounds containing a 2-(benzylidene)hexanoic acid scaffold as multi-target directed γ-secretase-modulators. Broad structural variations were undertaken to elucidate the structure–activity-relationships at the 5-position of the aromatic core. Compound 13 showed the most potent activity profile with IC50 values of 0.79 μM (Aβ42), 0.3 μM (5-lipoxygenase) and an EC50 value of 4.64 μM for PPARγ-activation. This derivative is the first compound exhibiting low micromolar to nanomolar activities for these three targets. Combining γ-secretase-modulation, PPARγ-agonism and inhibition of 5-lipoxygenase in one compound could be a …

Clinical BiochemistryPharmaceutical SciencePeroxisome proliferator-activated receptorInflammationDiseasePharmacologyInhibitory postsynaptic potentialBiochemistryStructure-Activity Relationshipchemistry.chemical_compoundAlzheimer DiseaseDrug DiscoverymedicineHumansLipoxygenase Inhibitorsγ secretaseCaproatesMolecular BiologyHexanoic acidchemistry.chemical_classificationArachidonate 5-LipoxygenasebiologyOrganic ChemistryPPAR gammachemistryBiochemistryArachidonate 5-lipoxygenasebiology.proteinMolecular MedicineAmyloid Precursor Protein Secretasesmedicine.symptomDerivative (chemistry)Bioorganic & Medicinal Chemistry Letters
researchProduct

Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?

2007

Curcumin binds to the amyloid beta peptide (Abeta) and inhibits or modulates amyloid precursor protein (APP) metabolism. Therefore, curcumin-derived isoxazoles and pyrazoles were synthesized to minimize the metal chelation properties of curcumin. The decreased rotational freedom and absence of stereoisomers was predicted to enhance affinity toward Abeta(42) aggregates. Accordingly, replacement of the 1,3-dicarbonyl moiety with isosteric heterocycles turned curcumin analogue isoxazoles and pyrazoles into potent ligands of fibrillar Abeta(42) aggregates. Additionally, several compounds are potent inhibitors of tau protein aggregation and depolymerized tau protein aggregates at low micromolar …

CurcuminMagnetic Resonance SpectroscopyAmyloid betaStereochemistryTau proteinPeptidetau ProteinsBiochemistrychemistry.chemical_compoundInhibitory Concentration 50Radioligand AssayAlzheimer Diseasemental disordersDrug DiscoveryAmyloid precursor proteinFluorescence Resonance Energy TransferMoietyAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsEnzyme InhibitorsCells CulturedCell ProliferationPharmacologychemistry.chemical_classificationAmyloid beta-PeptidesbiologyOrganic ChemistryP3 peptideIsoxazolesBiochemistrychemistrybiology.proteinCurcuminMolecular MedicinePyrazolesAmyloid Precursor Protein SecretasesAmyloid precursor protein secretaseChickensChemMedChem
researchProduct

Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins.

2001

The L1 adhesion molecule plays an important role in axon guidance and cell migration in the nervous system. L1 is also expressed by many human carcinomas. In addition to cell surface expression, the L1 ectodomain can be released by a metalloproteinase, but the biological function of this process is unknown. Here we demonstrate that membrane-proximal cleavage of L1 can be detected in tumors and in the developing mouse brain. The shedding of L1 involved a disintegrin and metalloproteinase (ADAM)10, as transfection with dominant-negative ADAM10 completely abolishes L1 release. L1-transfected CHO cells (L1-CHO) showed enhanced haptotactic migration on fibronectin and laminin, which was blocked …

CytoplasmIntegrinsL1; shedding; ADAM10; cell migration; integrinsADAM10IntegrinGene ExpressionCHO CellsBiologyArticle03 medical and health sciencesParacrine signallingMice0302 clinical medicineCell MovementCricetinaeEndopeptidasesTumor Cells CulturedAnimalsAspartic Acid EndopeptidasesHumansReceptors VitronectinFibrinolysinNeural Cell Adhesion Molecules030304 developmental biology0303 health sciencesBinding SitesMembrane GlycoproteinsCell adhesion moleculeCell MembraneAntibodies MonoclonalBrainCell migrationBiological TransportCell BiologyMolecular biologyPeptide FragmentsCell biologyFibronectinAutocrine CommunicationEctodomainSolubility030220 oncology & carcinogenesisbiology.proteinNeural cell adhesion moleculeAmyloid Precursor Protein SecretasesLeukocyte L1 Antigen ComplexOligopeptidesThe Journal of cell biology
researchProduct

Amyloid Precursor-like Protein 1 Influences Endocytosis and Proteolytic Processing of the Amyloid Precursor Protein

2005

Ectodomain shedding of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer disease amyloid beta peptide (Abeta). The molecular mechanisms underlying the control of APP shedding remain little understood but are in part dependent on the low density lipoprotein receptor-related protein (LRP), which is involved in APP endocytosis. Here, we show that the APP homolog APLP1 (amyloid precursor-like protein 1) influences APP shedding. In human embryonic kidney 293 cells expression of APLP1 strongly activated APP shedding by alpha-secretase and slightly reduced beta-secretase cleavage. As revealed by domain deletion analysis, the increase in APP shedding re…

CytoplasmTime FactorsRecombinant Fusion ProteinsAmino Acid MotifsBlotting WesternGenetic VectorsEndocytic cycleCHO CellsTransfectionEndocytosisBiochemistryCell LineAmyloid beta-Protein PrecursorGenes ReporterCricetinaeChlorocebus aethiopsEndopeptidasesmental disordersAmyloid precursor proteinAnimalsAspartic Acid EndopeptidasesHumansImmunoprecipitationAPLP1Molecular BiologyModels GeneticbiologyChemistryHEK 293 cellsP3 peptideCell BiologyEndocytosisProtein Structure TertiaryMicroscopy FluorescenceBiochemistryAlpha secretaseEctodomainCOS Cellsbiology.proteinAmyloid Precursor Protein SecretasesPeptidesGene DeletionPlasmidsJournal of Biological Chemistry
researchProduct

The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity

2005

The cellular prion protein (PrP(c)) is physiologically cleaved in the middle of its 106-126 amino acid neurotoxic region at the 110/111 downward arrow112 peptidyl bond, yielding an N-terminal fragment referred to as N1. We recently demonstrated that two disintegrins, namely ADAM10 and ADAM17 (TACE, tumor necrosis factor alpha converting enzyme) participated in both constitutive and protein kinase C-regulated generation of N1, respectively. These proteolytic events were strikingly reminiscent of those involved in the so-called "alpha-secretase pathway" that leads to the production of secreted sAPPalpha from betaAPP. We show here, by transient and stable transfection analyses, that ADAM9 also…

DNA ComplementaryADAM10Gene ExpressionTransfectionBiochemistryDNA AntisenseCell LineAmyloid beta-Protein PrecursorMice03 medical and health sciences0302 clinical medicineEndopeptidasesDisintegrinAnimalsAspartic Acid EndopeptidasesHumansPrPC Proteins[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyProtein kinase AMolecular Biology030304 developmental biologyMice Knockout0303 health sciencesbiologyHEK 293 cells030302 biochemistry & molecular biologyMembrane ProteinsTransfectionCell BiologyFibroblastsPeptide FragmentsADAM ProteinsBiochemistryCell culturebiology.proteinAdditions and CorrectionsAmyloid Precursor Protein SecretasesADAM9Amyloid precursor protein secretase030217 neurology & neurosurgery
researchProduct

Tumor necrosis factor-alpha converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulat…

2003

Tumor necrosis factor-alpha converting enzyme (TACE or ADAM17) is a member of the ADAM (a disintegrin and metalloproteinase) family of type I membrane proteins and mediates the ectodomain shedding of various membrane-anchored signaling and adhesion proteins. TACE is synthesized as an inactive zymogen, which is subsequently proteolytically processed to the catalytically active form. We have identified the proprotein-convertases PC7 and furin to be involved in maturation of TACE. This maturation is negatively influenced by the phorbol ester phorbol-12-myristate-13-acetate (PMA), which decreases the cellular amount of the mature form of TACE in PMA-treated HEK293 and SH-SY5Y cells. Furthermore…

DNA ComplementaryTime FactorsADAM10Blotting WesternGenetic VectorsADAM17 ProteinTransfectionBiochemistryCell LineAmyloid beta-Protein PrecursorAlzheimer DiseaseZymogenEndopeptidasesPhorbol EstersCell AdhesionTumor Cells CulturedAnimalsAspartic Acid EndopeptidasesHumansSubtilisinsProtein kinase A signalingFurinProtein Kinase CProtein kinase CFurinMetalloproteinasebiologyChemistryMetalloendopeptidasesCyclic AMP-Dependent Protein KinasesPeptide FragmentsRatsCell biologyADAM ProteinsEctodomainBiochemistrybiology.proteinTetradecanoylphorbol AcetateCattleTumor necrosis factor alphaProprotein ConvertasesAmyloid Precursor Protein SecretasesSignal TransductionEuropean Journal of Biochemistry
researchProduct

Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production

2004

Increased Abeta42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Abeta42. Among the more potent Abeta42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Abeta42, including multiple COX-2-selective derivatives of two Abeta42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Abeta42. These compounds seem to target the gamma-secretase complex, increasing gamma-secretase-catalyzed production of Abeta42 in vitro. Short-term in vivo studies show that two Abeta42-raising comp…

Enzyme-Linked Immunosorbent AssayEndogenyProtein Serine-Threonine KinasesPharmacologyTransfectionMass SpectrometryGeneral Biochemistry Genetics and Molecular BiologyPresenilinCell LineFenofibrateAlzheimer DiseaseIn vivoEndopeptidasesmedicineAspartic Acid EndopeptidasesHumansImmunoprecipitationCyclooxygenase InhibitorsProtein precursorHypolipidemic AgentsSulfonamidesrho-Associated KinasesAmyloid beta-PeptidesFenofibratebusiness.industryAnti-Inflammatory Agents Non-SteroidalIntracellular Signaling Peptides and ProteinsBrainGeneral Medicinemedicine.diseaseIn vitroEnzyme ActivationBiochemistryCelecoxibPyrazolesFemaleAmyloid Precursor Protein SecretasesAlzheimer's diseaserhoA GTP-Binding ProteinbusinessAntilipidemic Agentmedicine.drugNature Medicine
researchProduct

Expression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5′-Untranslated Region*

2010

Proteolytic processing of the amyloid precursor protein by alpha-secretase prevents formation of the amyloid beta-peptide (Abeta), which is the main constituent of amyloid plaques in brains of Alzheimer disease (AD) patients. alpha-Secretase activity is decreased in AD, and overexpression of the alpha-secretase ADAM10 (a disintegrin and metalloprotease 10) in an AD animal model prevents amyloid pathology. ADAM10 has a 444-nucleotide-long, very GC-rich 5'-untranslated region (5'-UTR) with two upstream open reading frames. Because similar properties of 5'-UTRs are found in transcripts of many genes, which are regulated by translational control mechanisms, we asked whether ADAM10 expression is…

Five prime untranslated regionenzymology [Brain]ADAM10ADAM10 protein humanBACE1-ASgenetics [Amyloid Precursor Protein Secretases]genetics [Alzheimer Disease]genetics [ADAM Proteins]BiochemistryGene Expression Regulation Enzymologicbiosynthesis [Membrane Proteins]ADAM10 ProteinAlzheimer DiseaseChlorocebus aethiopsAmyloid precursor proteinProtein biosynthesisbiosynthesis [Amyloid beta-Peptides]genetics [Amyloid beta-Peptides]AnimalsHumansGene RegulationMolecular BiologySequence Deletionbiosynthesis [ADAM Proteins]Amyloid beta-PeptidesbiologyBase SequenceP3 peptideenzymology [Alzheimer Disease]BrainMembrane ProteinsCell BiologyMolecular biologyBiochemistry of Alzheimer's diseasegenetics [Membrane Proteins]ADAM Proteinsbiosynthesis [Amyloid Precursor Protein Secretases]Protein Biosynthesisddc:540COS Cellsbiology.proteinAmyloid Precursor Protein Secretases5' Untranslated RegionsAmyloid precursor protein secretase
researchProduct

Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.

2006

The amyloid-beta (Abeta) peptides and specifically the highly amyloidogenic isoform Abeta42 appear to be key agents in the pathogenesis of familial and sporadic forms of Alzheimer's disease (AD). The final step in the generation of Abeta from the amyloid precursor protein is catalyzed by the multiprotein complex gamma-secretase, which constitutes a prime drug target for prevention and therapy of the disease. However, highly potent gamma-secretase inhibitors that block formation of all Abeta peptides have provoked troubling side effects in preclinical animal models of AD. This toxicity can be readily explained by the promiscuous substrate specificity of gamma-secretase and its essential role…

Gene isoformendocrine systemClinical Trials as TopicNonsteroidalAmyloid beta-Peptidesmedicine.drug_classAnti-Inflammatory Agents Non-SteroidalPharmacologyIbuprofenAmyloid β peptideAnti-inflammatoryPathogenesischemistry.chemical_compoundNeurologychemistryAlzheimer DiseasemedicineAnimalsHumansNeurology (clinical)γ secretaseAmyloid Precursor Protein SecretasesGamma secretasemedicine.drugNeuro-degenerative diseases
researchProduct

Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ…

2010

γ-Secretase modulators (GSMs) inhibit the generation of amyloidogenic Aβ42 peptides and are promising agents for treatment or prevention of Alzheimer's disease (AD). Recently, a second generation of GSMs with favorable pharmacological properties has emerged, but preclinical studies to assess their efficacy in vivo are lacking. Such studies rely on transgenic mouse models that express amyloid precursor protein (APP) and presenilin (PSEN) mutations associated with early-onset familial AD. Previously, we have shown that certain PSEN1 mutations attenuated the response of cultured cells to GSMs and potentially confound in vivo studies in AD mouse models. However, different combinations of famili…

Genetically modified mouseMutationbiologymedicine.disease_causemedicine.diseaseBiochemistryPhenotypePresenilinCellular and Molecular NeuroscienceIn vivomedicinePSEN1Amyloid precursor proteinbiology.proteinCancer researchAlzheimer's diseaseNeuroscienceJournal of Neurochemistry
researchProduct